IDNA - PDS Biotechnology: Speculative Biotech Worth Buying After Latest Data

May, 27 2022 01:36 PM iShares Genomics Immunology and Healthcare

Positive results were announced from the phase 2 NCI-led PDS0101 triple-combination study in patients with HPV16+ cancers; both CPI naive and CPI refractory patients were helped.
Positive results were also announced from the phase 2 study using PDS0101 + Keytruda for recurrent or metastatic head and neck cancer patients.
Proof of concept for PDS Biotechnology's Versamune T-cell activating technology platform was established.
PDS Biotechnology had $58.9 million in cash as of March 31, 2022; enough cash to fund its operations into 2024.

For further details see:

Company Name:	iShares Genomics Immunology and Healthcare
Stock Symbol:	IDNA
Market:	NYSE